Monitor the SITC poster presentation on November 7, 2026 for any new efficacy or safety signals that could inform the ongoing phase 3 NSCLC trial or regulatory path. No immediate stock-moving catalyst from this announcement alone.
Price Chart
Executive Summary
Candel Therapeutics announced that a late-breaking abstract from its phase 2 PrTK05 trial of aglatimagene besadenovec in localized prostate cancer has been accepted for a poster presentation at the SITC 41st Annual Meeting in November 2026. The presentation will include longitudinal immune-profiling, biodistribution, and viral shedding data. This is a routine scientific conference update with no new clinical data or regulatory decision disclosed.
Key Facts
- Late-breaking abstract from phase 2 PrTK05 trial of aglatimagene besadenovec accepted for poster at SITC 41st Annual Meeting (Nov 4-8, 2026, Phoenix).
- Presentation will feature longitudinal immune-profiling, biodistribution, and viral shedding data in localized intermediate-risk prostate cancer.
- Aglatimagene is not approved by FDA or any regulatory authority for any use.
- Company is clinical-stage with ongoing phase 3 trial in NSCLC and phase 1b trial in rHGG.
Financial Impact
No financial data disclosed; no revenue, deal value, or guidance provided.
Risk Factors
- No new clinical data or regulatory decision in this release; stock may not react.
- Aglatimagene remains investigational with no approved indications.
- Company is pre-revenue and dependent on future trial results and financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3391303 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 3d ago | Press Release | $8.65 | awaiting T+60 | awaiting T+60 | $8.33 (−3.70%) |
Oct 1, 2026 4w ago | Press Release | $10.16 | awaiting T+60 | awaiting T+60 | $8.33 (−18.01%) |
Sep 30, 2026 4w ago | Press Release | $10.44 | awaiting T+60 | awaiting T+60 | $8.33 (−20.21%) |
Sep 10, 2026 7w ago | 8-K | $11.33 | awaiting T+60 | awaiting T+60 | $8.33 (−26.48%) |
Sep 9, 2026 7w ago | 8-K | $11.33 | awaiting T+60 | awaiting T+60 | $8.33 (−26.48%) |
Aug 15, 2026 11w ago | Institutional Cluster | $12.16 | awaiting T+60 | awaiting T+60 | $8.33 (−31.50%) |
Aug 13, 2026 11w ago | 8-K | No price | awaiting T+60 | awaiting T+60 | No price |
Aug 13, 2026 11w ago | Press Release | $11.80 | awaiting T+60 | awaiting T+60 | $8.33 (−29.41%) |
Aug 3, 2026 12w ago | Press Release | $10.07 $8.16 | ▼ −18.97% | ▼ −20.75% | $8.33 (−17.28%) |
Jul 1, 2026 17w ago | Insider Cluster | $9.83 $11.19 | ▲ +13.84% | ▲ +11.04% | $8.33 (−15.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers